0000000000455405

AUTHOR

Rinaldi L.

showing 4 related works from this author

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a m…

2023

BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available.MethodsWe carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recrui…

neoadjuvant treatmentCancer ResearchOncologytriple negative breast canceradjuvant capecitabineresidual tumorsresidual tumortreatment discontinuationFrontiers in Oncology
researchProduct

The multifaceted spectrum of liver cirrhosis in older hospitalised patients: Analysis of the REPOSI registry

2021

Abstract Background Knowledge on the main clinical and prognostic characteristics of older multimorbid subjects with liver cirrhosis (LC) admitted to acute medical wards is scarce. Objectives To estimate the prevalence of LC among older patients admitted to acute medical wards and to assess the main clinical characteristics of LC along with its association with major clinical outcomes and to explore the possibility that well-distinguished phenotypic profiles of LC have classificatory and prognostic properties. Methods A cohort of 6,193 older subjects hospitalised between 2010 and 2018 and included in the REPOSI registry was analysed. Results LC was diagnosed in 315 patients (5%). LC was ass…

Patient Discharge.RegistrieAgingmedicine.medical_specialtyCirrhosisphenotypeliver cirrhosisAftercareOlder populationNOolder people03 medical and health sciencesSocial support0302 clinical medicinePhenotypic analysisOlder patientsInternal medicinemedicineHumansRegistries030212 general & internal medicineLS4_4Hospital MortalityAgedbusiness.industryhospitalisationliver cirrhosiHazard ratioConfoundingphenotypesGeneral Medicinemedicine.diseasedisability; hospitalisation; liver cirrhosis; mortality; older people; phenotypes; Aged; Hospital Mortality; Hospitalization; Humans; Liver Cirrhosis; Registries; Aftercare; Patient DischargemortalityPatient DischargeHospitalizationdisabilityCohortdisability hospitalisation liver cirrhosis mortality older people phenotypes030211 gastroenterology & hepatologyGeriatrics and Gerontologybusinessdisability; hospitalisation; liver cirrhosis; mortality; older people; phenotypesHuman
researchProduct

Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register)

2021

Purpose: To evaluate clinical features, treatments, and outcomes of osteoporotic patients admitted to internal medicine and geriatric wards compared with non-osteoporotic patients (REPOSI registry). Methods: We studied 4714 patients hospitalized between 2010 and 2016. We reported age, sex, educational level, living status, comorbidities and drugs taken, Cumulative Illness Rating Scale (CIRS), Barthel Index, Short-Blessed Test, 4-item Geriatric Depression Scale, serum hemoglobin, creatinine, and clinical outcomes. Osteoporosis was defined based on the diagnoses recorded at admission, according to the following ICD9: 733, 805-813, 820-823. Results: Twelve percent of the patients had a preadmi…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosis030209 endocrinology & metabolismNO03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyRating scaleInternal medicineDiabetes mellitusVitamin D and neurologyInternal MedicineMedicineeracturesHumansBisphosphonateMedical diagnosisbisphosphonates; eractures; osteoporosis; vitamin DVitamin DAgedCreatinineRehabilitationLS7_9Bisphosphonates; Fractures; Osteoporosis; Vitamin D.business.industryOsteoporosiBisphosphonatesmedicine.diseaseHospitalizationFracturechemistryItaly030220 oncology & carcinogenesisOsteoporosisGeriatric Depression ScaleVitamin D.businessBisphosphonates; Fractures; Osteoporosis; Vitamin D; Aged; Hospitalization; Humans; Internal Medicine; Italy; Vitamin D; OsteoporosisBisphosphonates; Fractures; Osteoporosis; Vitamin DFractures
researchProduct

Search for Magnetic Monopoles and Stable High-Electric-Charge Objects in 13 Tev Proton-Proton Collisions with the ATLAS Detector

2020

We thank CERN for the very successful operation of the LHC, aswell as the support staff fromour institutionswithout whom ATLAS could not be operated efficiently. We acknowledge the support of ANPCyT, Argentina; YerPhI, Armenia; ARC, Australia; FWF, BMWFW, Austria; ANAS, Azerbaijan; SSTC, Belarus; CNPq, FAPESP, Brazil; NSERC, CFI, NRC, Canada; CERN; CONICYT, Chile; CAS, NSFC, MOST, China; COLCIENCIAS, Colombia; VSC CR, MSMT CR, MPO CR, Czech Republic; DNSRC, DNRF, Denmark; IN2P3-CNRS, CEA-DRF/IRFU, France; SRNSFG, Georgia; MPG, HGF, BMBF, Germany; GSRT, Greece; RGC, Hong Kong SAR, Hong Kong China; Benoziyo Center, ISF, Israel; INFN, Italy; JSPS, MEXT, Japan; JINR; CNRST, Morocco; NWO, Nether…

electric [charge]Drell-Yan process:Kjerne- og elementærpartikkelfysikk: 431 [VDP]Magnetic monopolesProton13000 GeV-cmsPhysics::Instrumentation and Detectorselectromagnetic [calorimeter]magnetic [charge]General Physics and Astronomy7. Clean energy01 natural scienceschannel cross section: upper limitHigh Energy Physics - Experimentmagnetic monopole: massSubatomär fysikparticle: stabilityHigh Energy Physics - Experiment (hep-ex)magnetic monopole: pair productionSubatomic Physicsscattering [p p][PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]tracking detectorstability [particle]0 [spin]1/2 [spin]Particle productionHadron collidersPhysicsRange (particle radiation)Large Hadron Colliderupper limit [channel cross section]DetectorSettore FIS/01 - Fisica Sperimentalemass [magnetic monopole]ATLAS3. Good health:Nuclear and elementary particle physics: 431 [VDP]CERN LHC Collhigh [ionization]ATLAS Detectorslower limit [mass]atlas; lhc; higgs;colliding beams [p p]pair production [magnetic monopole]Particle Physics - ExperimentsignatureDirect Productionp p: scatteringHigh-Ionizationdirect production [magnetic monopole]530 PhysicsCiências Naturais::Ciências Físicasmass: lower limit:Ciências Físicas [Ciências Naturais]Magnetic monopolespin: 0FOS: Physical sciencesLHC ATLAS High Energy Physicsddc:500.2Electromagnetic CalorimeterElectric chargeComputer Science::Digital LibrariesChargeNuclear physicsionization: high0103 physical sciencesTransition Radiation Trackersddc:530High Energy Physicsspin: 1/2010306 general physicsCiencias ExactasATLAS Collaborationcharge: magneticmagnetic monopolesS028CScience & Technologyhep-excharge: electricFísicaCharge (physics)triggerPair productioncalorimeter: electromagneticProton Proton CollisionsExperimental High Energy PhysicsMagnetic ChargesElementary Particles and FieldsHigh Energy Physics::Experimenttransition radiationHadron-hadron collisionsp p: colliding beamsmagnetic monopole: direct productionexperimental resultsPhysical Review Letters
researchProduct